Rush to end drug rebates may be bad for patients, payers, and pharma
JOE RAEDLE/GETTY IMAGES
Eliminating rebates for prescription drugs could lead to higher prices if companies can't keep confidential the prices they negotiate for drugs.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario